{{DrugProjectFormSinglePage
|authorTag=Ammu Susheela, M.D.[1]
|genericName=Ranitidine
|aOrAn=a
|drugClass=antacid
|indicationType=treatment
|indication=relieves heartburn associated with acid indigestion and sour stomach
prevents heartburn associated with acid indigestion and sour stomach brought on by certain foods and beverages
|adverseReactions=headache, constipation, diarrhea, abdominal pain
|blackBoxWarningTitle=Title
|blackBoxWarningBody=ConditionName:
Content
|fdaLIADAdult=* Relieves heartburn associated with acid indigestion and sour stomach
Prevents heartburn associated with acid indigestion and sour stomach brought on by certain foods and beverages
Helicobacter pylori gastrointestinal tract infection: (quadruple therapy) ranitidine 150 mg ORALLY twice daily in combination with metronidazole 250 mg ORALLY four times a day, bismuth subsalicylate 525 mg ORALLY four times a day, and tetracycline hydrochloride 500 mg ORALLY four times a day 10 to 14 days.
Indigestion, Non-ulcer: (prophylaxis) 75 to 150 mg ORALLY 30 to 60 min before eating or drinking, MAX 300 mg/day [9]
Indigestion, Non-ulcer: (treatment) 75 to 150 mg ORALLY once or twice daily, MAX 300 mg/day.
Stress ulcer; Prophylaxis: 150 mg NG or ORALLY twice daily.
Stress ulcer; Prophylaxis: 50 mg IV every 6-8 hr.
Stress ulcer; Prophylaxis: 6.25 mg/hr IV continuous infusion.
Zollinger-Ellison syndrome: (oral) 150 mg ORALLY twice daily; up to 6 grams/day have been used in patients with severe disease [4]
Zollinger-Ellison syndrome: (intermittent injection or infusion) 50 mg IV/IM every 6 to 8 hours.
Zollinger-Ellison syndrome: (continuous IV infusion) 1 mg/kg/hr; if after 4 hours, gastric acid output is greater than 10 mEq/hr or patient becomes symptomatic, dose may be increased in 0.5-mg/kg/hr increments; MAX 2.5 mg/kg/hr or 220 mg/hr.
|offLabelPedGuideSupport=There is limited information regarding Off-Label Guideline-Supported Use of Ranitidine (oral) in pediatric patients.
|offLabelPedNoGuideSupport=There is limited information regarding Off-Label Non–Guideline-Supported Use of Ranitidine (oral) in pediatric patients.
|warnings======Allergy alert=====
Do not use if you are allergic to ranitidine or other acid reducers
Do not use if you have trouble or pain swallowing food, vomiting with blood, or bloody or black stools. These may be signs of a serious condition.
with other acid reducers
if you have kidney disease, except under the advice and supervision of a doctor
Ask a doctor before use if you have
frequent chest pain
frequent wheezing, particularly with heartburn
unexplained weight loss
nausea or vomiting
stomach pain
had heartburn over 3 months. This may be a sign of a more serious condition.
heartburn with lightheadedness, sweating, or dizziness
chest pain or shoulder pain with shortness of breath; sweating; pain spreading to arms, neck or shoulders; or lightheadedness
Stop use and ask a doctor if your heartburn continues or worsens
you need to take this product for more than 14 days
If pregnant or breast-feeding, ask a health professional before use.
Keep out of reach of children.
|FDAPregCat=B
|useInPregnancyFDA=* Pregnancy Category
|AUSPregCat=B1
|useInPregnancyAUS=* Australian Drug Evaluation Committee (ADEC) Pregnancy Category
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Ranitidine (oral) in women who are pregnant.
|useInLaborDelivery=There is no FDA guidance on use of Ranitidine (oral) during labor and delivery.
|useInNursing=Infant risk cannot be ruled out.
|useInPed=There is no FDA guidance on the use of Ranitidine (oral) with respect to pediatric patients.
|useInGeri=There is no FDA guidance on the use of Ranitidine (oral) with respect to geriatric patients.
|useInGender=There is no FDA guidance on the use of Ranitidine (oral) with respect to specific gender populations.
|useInRace=There is no FDA guidance on the use of Ranitidine (oral) with respect to specific racial populations.
|useInRenalImpair=There is no FDA guidance on the use of Ranitidine (oral) in patients with renal impairment.
|useInHepaticImpair=There is no FDA guidance on the use of Ranitidine (oral) in patients with hepatic impairment.
|useInReproPotential=There is no FDA guidance on the use of Ranitidine (oral) in women of reproductive potentials and males.
|useInImmunocomp=There is no FDA guidance one the use of Ranitidine (oral) in patients who are immunocompromised.
|administration=* Oral
Intravenous
|monitoring=There is limited information regarding Monitoring of Ranitidine (oral) in the drug label.
Description
|IVCompat=There is limited information regarding IV Compatibility of Ranitidine (oral) in the drug label.
| ChemSpiderID_Ref = Y
| ChemSpiderID = 571454
| UNII_Ref = Y
| UNII = 884KT10YB7
| KEGG_Ref = Y
| KEGG = D00422
| ChEBI_Ref = N
| ChEBI = 8776
| ChEMBL_Ref = N
| ChEMBL = 1790041
| C=13 | H=22 | N=4 | O=3 | S=1
| molecular_weight = 314.4 g/mol
| smiles = [O-][N+](=O)\C=C(\NC)NCCSCc1oc(cc1)CN(C)C
| InChI = 1/C13H22N4O3S/c1-14-13(9-17(18)19)15-6-7-21-10-12-5-4-11(20-12)8-16(2)3/h4-5,9,14-15H,6-8,10H2,1-3H3/b13-9-
| InChIKey = VMXUWOKSQNHOCA-LCYFTJDEBT
| StdInChI_Ref = N
| StdInChI = 1S/C13H22N4O3S/c1-14-13(9-17(18)19)15-6-7-21-10-12-5-4-11(20-12)8-16(2)3/h4-5,9,14-15H,6-8,10H2,1-3H3
| StdInChIKey_Ref = N
| StdInChIKey = VMXUWOKSQNHOCA-UHFFFAOYSA-N
}}
|mechAction=* Ranitidine is a competitive, reversible inhibitor of the action of histamine at the histamine H2-receptors found in gastric cells. This results in decreased gastric acid secretion and gastric volume, and reduced hydrogen ion concentration.
|structure=*
Half-life elimination: With normal renal function, ranitidine taken orally has a half-life of 2.5–3 hours. If taken intravenously, the half-life is generally 2-2.5 hours in a patient with normal creatinine clearance.
Excretion
The primary route of excretion is the urine. In addition, approximately 30% of the orally administered dose is collected in the urine as non-absorbed drug in 24 hours.
Elderly
In the elderly population, the plasma half-life of ranitidine is prolonged to 3–4 hours secondary to decreased kidney function causing decreased clearance.
Children
In general, studies looking pediatric patients (aged 1 month to 16 years) have showed no significant differences in pharmacokinetic parameter values in comparison to healthy adults, when correction is made for body weigh
|nonClinToxic=There is limited information regarding Nonclinical Toxicology of Ranitidine (oral) in the drug label.
|clinicalStudies=There is limited information regarding Clinical Studies of Ranitidine (oral) in the drug label.
This image is provided by the National Library of Medicine.
|fdaPatientInfo=* Adults and children 12 years and over:
to relieve symptoms, swallow 1 tablet with a glass of water to prevent symptoms, swallow 1 tablet with a glass of water 30 to 60 minutes before eating food or drinking beverages that cause heartburn
can be used up to twice daily (do not take more than 2 tablets in 24 hours)
TAMPER EVIDENT: DO NOT USE IF THE CARTON OR PRINTED FOIL UNDER CAP IS OPEN OR TORN.
|alcohol=* Alcohol-Ranitidine (oral) interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
| CAS_number_Ref = 
| ChEBI = 8776
| ChEMBL_Ref = 
01.png){kind=link}
